GCT 102
Alternative Names: GCT102Latest Information Update: 28 Apr 2024
Price :
$50 *
At a glance
- Originator Kidswell Bio
- Developer Kidswell Bio; Mochida Pharmaceutical
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Gastrointestinal disorders
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for research development in Gastrointestinal-disorders in Japan (Parenteral)
- 01 Jul 2021 Gene Techno Science is now called Kidswell Bio
- 23 May 2020 Early research in Gastrointestinal disorders in Japan (Parenteral) (Kidswell Bio pipeline, November 2021)